Skip to main content
. 2019 Apr 26;11(5):949. doi: 10.3390/nu11050949

Table 3.

Baseline and final values of lipids and apolipoproteins by group allocation.

Baseline One Month Three Months p Group p Time p Interaction
Total cholesterol, mmol/L
 Nutraceutical 6.07 (5.83 to 6.32) a 5.38 (5.12 to 5.64) b 5.22 (5.58 to 6.08) b 0.326 <0.001 <0.001
 Placebo 5.83 (5.58 to 6.08) 5.66 (5.40 to 5.92) 5.66 (5.38 to 5.94)
LDL-cholesterol, mmol/L
 Nutraceutical 3.90 (3.68 to 4.14) a 3.32 (3.10 to 3.54) b 3.13 (2.92 to 3.35) b 0.192 <0.001 <0.001
 Placebo 3.71 (3.47 to 3.94) 3.56 (3.34 to 3.78) 3.59 (3.38 to 3.78)
HDL-cholesterol, mmol/L
 Nutraceutical 1.44 (1.26 to 1.62) 1.47 (1.30 to 1.63) 1.49 (1.31 to 1.66) 0.432 0.933 0.337
 Placebo 1.57 (1.40 to 1.75) 1.55 (1.39 to 1.72) 1.54 (1.37 to 1.72)
Triglycerides, mmol/L
 Nutraceutical 1.53 (1.19 to 1.86) 1.29 (1.08 to 1.50) 1.35 (1.11 to 1.60) 0.251 0.058 0.507
 Placebo 1.26 (0.92 to 1.60) 1.19 (0.97 to 1.39) 1.13 (0.89 to 1.38)
Non-HDL-cholesterol, mmol/L
 Nutraceutical 4.63 (4.37 to 4.90) a 3.91 (3.63 to 4.19) b 3.73 (3.47 to 3.99) b 0.691 <0.001 <0.001
 Placebo 4.26 (3.99 to 4.53) 4.10 (3.83 to 4.38) 4.11 (3.85 to 4.38)
Apo B, mg/dL
 Nutraceutical 116.8 (110.4 to 123.2) a 102.3 (94.8 to 109.8) b 101.0 (94.6 to 107.4) b 0.909 <0.001 <0.001
 Placebo 108.3 (101.9 to 114.7) 105.1 (97.6 to 112.7) 105.1 (98.7 to 111.5)
Apo A1, mg/dL
 Nutraceutical 154.4 (144.0 to 164.7) 160.3 (149.9 to 170.6) 160.3 (149.5 to 171.0) 0.251 0.226 0.338
 Placebo 157.1 (146.8 to 167.5) 157.8 (147.5 to 168.2) 157.4 (146.6 to 168.1)

Values are means (SD). LDL: low-density lipoprotein; HDL: high-density lipoprotein; Apo B: apolipoprotein B; Apo A1: apolipoprotein A1. p value for one-way repeated-measures ANOVA for continuous variables (Group = treatment allocation; Time = baseline, one month, three months), a,b Different superscript letters in the same row mean that values were significantly different, p < 0.05, by ANOVA simple effect analyses with Bonferroni correction.